Abstract
ObjectivesWe did this study intending to compare the efficacy of rosuvastatin 5 mg and 10 mg in patients of type 2 diabetes mellitus with dyslipidemia by validating their effect on lipid profile and the side effects.MethodologyThis study was carried out at the outpatient department of a tertiary care hospital in Multan. Three hundred patients of both genders were included. The research approach employed a parallel-controlled, randomized study. After taking relevant history and physical examination, each patient’s fasting venous blood samples were taken and sent to the institutional laboratory to analyze glycated hemoglobin (HbA1c), baseline lipid levels for cholesterol, triglycerides, low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and high-density lipoprotein (HDL). Patients were divided into two groups based on the drug administered. One group was prescribed rosuvastatin 5 mg, and the other group was prescribed rosuvastatin 10 mg. Patients were followed up after six months to record the latest lipid profile. Data analysis was done through SPSS version 24.ResultsPatients in the two groups had similar lipid levels to start with. After six months of therapy, total serum cholesterol, triglycerides, and LDL-C were reduced to statistically significant levels in group two compared to group one. However, both groups showed a similar increase in serum levels of HDL-C. Patients treated with 10 mg rosuvastatin showed a slight decrease in BMI. Nine patients treated with 10 mg rosuvastatin reported myalgias compared to only one patient treated with a dose of 5 mg (p<0.005).ConclusionOur study concludes that both 5 mg and 10 mg of rosuvastatin exhibit the antihyperlipidemic effect, but high doses are associated with more side effects. Therefore, physicians should be aware of dose titration related to statins as it will ultimately lead to reduced cardiovascular mortality.
Highlights
Dyslipidemia is a well-studied risk factor for developing diseases associated with atherosclerosis, including coronary heart disease (CHD) and ischemic stroke
After six months of therapy, total serum cholesterol, triglycerides, and low-density lipoprotein (LDL)-C were reduced to statistically significant levels in group two compared to group one
Nine patients treated with 10 mg rosuvastatin reported myalgias compared to only one patient treated with a dose of 5 mg (p
Summary
Dyslipidemia is a well-studied risk factor for developing diseases associated with atherosclerosis, including coronary heart disease (CHD) and ischemic stroke. There is abundant evidence suggesting that lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular diseases (CVDs) [1,2]. Both European and USA guidelines for CVD prevention recommend using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) as first-line therapy for dyslipidemia [3]. It is well established that statins have antioxidant, anti-inflammatory effects, and antithrombotic properties that add to their clinical utility [6] They lead to improved endothelial dysfunction and a reduction in the growth of atherosclerotic plaque [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
